FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls

Adrien Holzgreve; Alexander Nitschmann; Sebastian H Maier; Marcel Büttner; Stephan Schönecker; Sebastian N Marschner; Daniel F Fleischmann; Stefanie Corradini; Claus Belka; Christian la Fougère; Raphael Bodensohn; Nathalie L Albert; Maximilian Niyazi

doi:10.1016/j.radonc.2024.110386

FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls

Radiother Oncol. 2024 Sep:198:110386. doi: 10.1016/j.radonc.2024.110386. Epub 2024 Jun 14.

Affiliations

¹ Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, USA. Electronic address: [email protected].
² Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
³ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.
⁴ Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
⁵ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany; German Cancer Consortium (DKTK), Munich, Germany.
⁶ Department of Nuclear Medicine, University Hospital Tübingen, Tübingen, Germany.
⁷ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
⁸ Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany; German Cancer Consortium (DKTK), Munich, Germany.
⁹ Bavarian Cancer Research Center (BZKF), Munich, Germany; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK), Tübingen, Germany.

PMID: 38880414
DOI: 10.1016/j.radonc.2024.110386

Abstract

PET is increasingly used for target volume definition in the radiotherapy of glioblastoma, as endorsed by the 2023 ESTRO-EANO guidelines. In view of its growing adoption into clinical practice and upcoming PET-based multi-center trials, this paper aims to assist in overcoming common pitfalls of FET PET-based target delineation in glioblastoma.

Keywords: AG-NRO-06; ARO-2024–01; Biological tumor volume (BTV); FET PET; Glioblastoma; NCT05871021; PRIDE trial (NOA-28; Treatment planning.

Publication types

Review

MeSH terms

Brain Neoplasms* / diagnostic imaging
Brain Neoplasms* / radiotherapy
Fluorodeoxyglucose F18
Glioblastoma* / diagnostic imaging
Glioblastoma* / radiotherapy
Humans
Positron-Emission Tomography* / methods
Radiopharmaceuticals
Radiotherapy Planning, Computer-Assisted* / methods

Substances

Fluorodeoxyglucose F18
Radiopharmaceuticals